Gossamer Bio, Inc.
Moat Score — Gossamer Bio, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Seralutinib's composition-of-matter and method-of-use patents on an inhaled PDGFR/CSF1R/c-KIT inhibitor are real IP, but they protect an asset whose Phase 3 PROSERA readout missed its prespecified primary-endpoint threshold, leaving the underlying clinical and regulatory case unsettled even where the patent estate itself is sound. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Gossamer has no manufacturing or scale cost advantage; as a clinical-stage company with no approved product, it is a net cash consumer, not a low-cost producer, and its R&D spend of $174.1M in FY2025 reflects the opposite of a cost edge. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved, commercialized product, Gossamer has no demonstrated pricing power today; any future pricing power is entirely contingent on seralutinib clearing a regulatory path the company has not yet secured. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A single-molecule pulmonary therapy has no network effect — value does not compound as more prescribers or patients adopt it, unlike a platform or marketplace business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once (if) approved, patients stabilized on an inhaled PAH/PH-ILD regimen face some switching friction, but with no product on the market yet and multiple approved alternatives (Winrevair, Tyvaso, Yutrepia) already established, Gossamer would be the one asking physicians to switch, not defending an installed base. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | PAH and PH-ILD are specialty, limited-prescriber markets, but Gossamer is a late entrant behind Merck's Winrevair and the approved PH-ILD incumbents, so there is no efficient-scale protection working in its favor yet. |